KAPA — Kairos Pharma Balance Sheet
0.000.00%
Last trade - 00:00- $11.63m
- $10.36m
Annual balance sheet for Kairos Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.014 | 0.073 | 0.437 | 0.093 | 1.27 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.014 | 0.073 | 0.437 | 0.101 | 4.17 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 0.014 | 0.775 | 1.04 | 0.965 | 5.77 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.357 | 1.94 | 1.63 | 2.4 | 0.992 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.357 | 1.94 | 2.21 | 3.04 | 0.992 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -0.343 | -1.17 | -1.18 | -2.08 | 4.78 |
| Total Liabilities & Shareholders' Equity | 0.014 | 0.775 | 1.04 | 0.965 | 5.77 |
| Total Common Shares Outstanding |